vs
Side-by-side financial comparison of BIOCRYST PHARMACEUTICALS INC (BCRX) and GLACIER BANCORP, INC. (GBCI). Click either name above to swap in a different company.
GLACIER BANCORP, INC. is the larger business by last-quarter revenue ($306.8M vs $156.4M, roughly 2.0× BIOCRYST PHARMACEUTICALS INC). Over the past eight quarters, GLACIER BANCORP, INC.'s revenue compounded faster (24.3% CAGR vs 19.6%).
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China.
Glacier Bancorp, Inc. is a regional multi-bank holding company headquartered in Kalispell, Montana, United States. It is a successor corporation to the Delaware corporation originally incorporated in 1990. The company provides personal and commercial banking services from 221 locations in Montana, Idaho, Utah, Washington, Wyoming, Colorado, Arizona, and, Nevada.
BCRX vs GBCI — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $156.4M | $306.8M |
| Net Profit | — | $82.1M |
| Gross Margin | — | — |
| Operating Margin | 13.6% | — |
| Net Margin | — | 26.8% |
| Revenue YoY | 7.5% | — |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.00 | $0.63 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $156.4M | $306.8M | ||
| Q4 25 | $406.6M | $306.5M | ||
| Q3 25 | $159.4M | $260.7M | ||
| Q2 25 | $163.4M | $240.6M | ||
| Q1 25 | $145.5M | $222.6M | ||
| Q4 24 | $131.5M | $223.0M | ||
| Q3 24 | $117.1M | $214.9M | ||
| Q2 24 | $109.3M | $198.7M |
| Q1 26 | — | $82.1M | ||
| Q4 25 | $245.8M | $63.8M | ||
| Q3 25 | $12.9M | $67.9M | ||
| Q2 25 | $5.1M | $52.8M | ||
| Q1 25 | $32.0K | $54.6M | ||
| Q4 24 | $-26.8M | $61.8M | ||
| Q3 24 | $-14.0M | $51.1M | ||
| Q2 24 | $-12.7M | $44.7M |
| Q1 26 | — | — | ||
| Q4 25 | 97.7% | — | ||
| Q3 25 | 98.6% | — | ||
| Q2 25 | 98.3% | — | ||
| Q1 25 | 96.9% | — | ||
| Q4 24 | 95.4% | — | ||
| Q3 24 | 97.3% | — | ||
| Q2 24 | 98.4% | — |
| Q1 26 | 13.6% | — | ||
| Q4 25 | 64.0% | 24.9% | ||
| Q3 25 | 18.6% | 32.7% | ||
| Q2 25 | 18.2% | 27.1% | ||
| Q1 25 | 14.6% | 28.5% | ||
| Q4 24 | -3.4% | 33.0% | ||
| Q3 24 | 6.6% | 28.9% | ||
| Q2 24 | 8.0% | 27.3% |
| Q1 26 | — | 26.8% | ||
| Q4 25 | 60.5% | 20.8% | ||
| Q3 25 | 8.1% | 26.0% | ||
| Q2 25 | 3.1% | 21.9% | ||
| Q1 25 | 0.0% | 24.5% | ||
| Q4 24 | -20.4% | 27.7% | ||
| Q3 24 | -12.0% | 23.8% | ||
| Q2 24 | -11.6% | 22.5% |
| Q1 26 | $0.00 | $0.63 | ||
| Q4 25 | $1.13 | $0.49 | ||
| Q3 25 | $0.06 | $0.57 | ||
| Q2 25 | $0.02 | $0.45 | ||
| Q1 25 | $0.00 | $0.48 | ||
| Q4 24 | $-0.13 | $0.55 | ||
| Q3 24 | $-0.07 | $0.45 | ||
| Q2 24 | $-0.06 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $259.0M | $1.4B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $4.2B |
| Total Assets | $465.1M | $31.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $259.0M | $1.4B | ||
| Q4 25 | $274.7M | — | ||
| Q3 25 | $212.9M | — | ||
| Q2 25 | $260.0M | — | ||
| Q1 25 | $295.1M | — | ||
| Q4 24 | $320.9M | — | ||
| Q3 24 | $96.8M | — | ||
| Q2 24 | $78.4M | — |
| Q1 26 | — | $4.2B | ||
| Q4 25 | $-119.2M | $4.2B | ||
| Q3 25 | $-387.9M | $3.6B | ||
| Q2 25 | $-421.6M | $3.5B | ||
| Q1 25 | $-451.9M | $3.3B | ||
| Q4 24 | $-475.9M | $3.2B | ||
| Q3 24 | $-468.6M | $3.2B | ||
| Q2 24 | $-475.6M | $3.1B |
| Q1 26 | $465.1M | $31.7B | ||
| Q4 25 | $514.2M | $32.0B | ||
| Q3 25 | $446.4M | $29.0B | ||
| Q2 25 | $457.2M | $29.0B | ||
| Q1 25 | $480.0M | $27.9B | ||
| Q4 24 | $490.4M | $27.9B | ||
| Q3 24 | $491.3M | $28.2B | ||
| Q2 24 | $472.4M | $27.8B |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BCRX
| ORLADEYO | $148.3M | 95% |
| Other revenues | $5.0M | 3% |
| License revenue | $3.0M | 2% |
GBCI
| Net Interest Income | $268.7M | 88% |
| Noninterest Income | $38.1M | 12% |
